(NASDAQ: SCYX) Scynexis's forecast annual revenue growth rate of 153.97% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.41%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Scynexis's revenue in 2025 is $3,746,000.On average, 1 Wall Street analysts forecast SCYX's revenue for 2025 to be $1,240,377,456, with the lowest SCYX revenue forecast at $1,240,377,456, and the highest SCYX revenue forecast at $1,240,377,456. On average, 1 Wall Street analysts forecast SCYX's revenue for 2026 to be $3,868,090,981, with the lowest SCYX revenue forecast at $3,868,090,981, and the highest SCYX revenue forecast at $3,868,090,981.
In 2027, SCYX is forecast to generate $1,571,326,690 in revenue, with the lowest revenue forecast at $1,571,326,690 and the highest revenue forecast at $1,571,326,690.